Innate Pharma (IPHYF) Research & Development (2019 - 2025)
Historic Research & Development for Innate Pharma (IPHYF) over the last 7 years, with Q2 2025 value amounting to -$23.2 million.
- Innate Pharma's Research & Development rose 2581.72% to -$23.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$170.4 million, marking a year-over-year decrease of 3532.49%. This contributed to the annual value of $55.5 million for FY2024, which is 784.84% down from last year.
- Innate Pharma's Research & Development amounted to -$23.2 million in Q2 2025, which was up 2581.72% from -$55.5 million recorded in Q4 2024.
- Innate Pharma's Research & Development's 5-year high stood at $705703.1 during Q2 2021, with a 5-year trough of -$60.3 million in Q4 2023.
- Its 5-year average for Research & Development is -$31.6 million, with a median of -$31.3 million in 2024.
- In the last 5 years, Innate Pharma's Research & Development soared by 10203.4% in 2021 and then plummeted by 11425668.68% in 2023.
- Quarter analysis of 5 years shows Innate Pharma's Research & Development stood at -$53.8 million in 2021, then surged by 99.9% to -$52709.0 in 2022, then plummeted by 114256.69% to -$60.3 million in 2023, then grew by 7.85% to -$55.5 million in 2024, then surged by 58.18% to -$23.2 million in 2025.
- Its last three reported values are -$23.2 million in Q2 2025, -$55.5 million for Q4 2024, and -$31.3 million during Q2 2024.